BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 4, 2015--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Brad Smith,
Chief Financial Officer, will present a corporate overview at the 17th
Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 4:30
p.m. Eastern Time at the Waldorf Astoria in New York City.
A live webcast will be accessible through Ocular’s website at www.ocutx.com
in the Investors section under Calendar of Events. A replay of the
presentation will also be available.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix's lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain, and
Phase 2 clinical development for glaucoma, allergic conjunctivitis, and
dry eye disease. The Company is also evaluating sustained-release
injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular
Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal
corneal incisions following cataract surgery.
Source: Ocular Therapeutix, Inc.
Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich,
212-213-0006
kminarovich@burnsmc.com
or
Media:
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
scorning@ocutx.com
